Seagen 2nd-qtr sales beat expectations

29 July 2022

US biotech Seagen (Nasdaq: SGEN) reported financial results for the second quarter ended June 30, 2022, after markets closed on Thursday.

Total revenues for the quarter were $497.5 million, a rise of 28%. Revenues in the 2022 periods reflected higher net product sales across the company’s commercial portfolio.

Net loss for the second quarter of 2022 was $134.8 million, compared with $84.6 million in the like 2021 period. Net loss per share for the second quarter was $0.73 versus $0.47 in the like year-ago quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK